You are here

CMLSg's comment on FAD: 1st line use of dasatinib, nilotinib, imatinib. CMLSg will not appeal this FAD.

In the circumstances we feel we have done all we can and that an appeal is not a positive option for us.

We feel our focus must now shift to ensuring that applications to the Cancer Drugs Fund are successful on every occasion a clinician selects that option to access dasatinib for patients in need. We continue to urge BMS to submit a Patient Access Scheme to the Department of Health. Please read full statement here: